ABSTRACT
Objective:To investigate clinical efficacy of nail removal in combination with periungual dermis-fat flap tamponade in the treatment of bilateral severe curved ingrown nails.Methods:A retrospective analysis was conducted on clinical data collected from 7 patients with bilateral severe curved ingrown nails visiting the hospital between January 2018 and January 2020. There were 3 males and 4 females, aged 25-49 years (average: 35 years) . All patients were treated with nail removal in combination with periungual dermis-fat flap tamponade at outpatient clinics.Results:All the 7 patients experienced primary healing of incisions without infections, and achieved pain relief 1-2 weeks after surgery. During the follow-up of 12 to 24 months, new nail plates grew back without curling deformity, no erythematous swelling occurred in the nail grooves, and no recurrence of paronychia was observed. All patients were satisfied with the clinical efficacy.Conclusion:Nail removal in combination with periungual dermis-fat flap tamponade is effective for the treatment of bilateral severe curved ingrown nails.
ABSTRACT
Objective To observe clinical curative effect of pregabalin combined with oxycodone hydrochloride controlled-release tablets on patients with postherpetic neuralgia(PHN).Methods 84 patients with PHN were randomly divided into observation group (n=42 cases) and control group ( n=42 cases); control group was given oxycodone hydrochloride controlled-release tablets, observation group received pregabalin combined with oxycodone hydrochloride controlled-release tablets treatment; NRS, dermatology life quality index (DLQI), Pittsburgh sleep quality score (PSQI) and SAS score were recoded before and after 1,2,4 weeks treatment; 24 h duration of pain, 24 h total sleep time , pain-relief effectiveness and adverse reactions of two group were compared.Results NRS, DLQI, PSQI and SAS score of two groups after 1,2,4 weeks treatment was lower than before treatment (P<0.05), all the scores of observation group were lower than control group (P <0.05); 24 h duration of pain of observation group was obviously less than control group ( P <0.05 ) , 24 h total sleep time was longer than control group ( P <0.05 ); dose of oxycodone hydrochloride controlled-release tablets in observation group was lower than control group ( P <0.05 ); pain relief effectiveness of observation group was obviously higher than that of control group (P<0.05); adverse reactions of observation group such as dry mouth, dizziness was higher than control group (P<0.05), the rest of the adverse reactions in two groups had no significant statistical difference.Conclusions Treatment of pregabalin combined with oxycodone hydrochloride controlled-release tablets are both effective and safe significantly, and can obviously improve the patient’ s pain symptoms, improve quality of life, preferable satisfactory comprehensive curative effect.
ABSTRACT
Objective To investigate the clinical significan ce of pelvic lymphadenectomy in advanced ovarian carcinoma. Methods A total of 86 cases of advanced ovarian cancer with surgical treatment were assigned to 3 groups according to the size of residual focus and the performanc e of pelvic lymphadenectomy. Group A consisted of 42 cases with pelvic lymphaden ectomy and the diameter of residual focus smaller than 2 cm; Group B, 26 cases, underwent pelvic lymphadenectomy but with the residual focus larger than 2 cm; Group C con sisted of 18 cases without pelvic lymphadenectomy and the diameter of residual f ocus larger than 2 cm. All patients received CAP chemotherapy for 6 to 8 course of treatment and were in similar clinical stages and pathological grading. Results The 5 year survival rate was 30.1% (13/42) in Group A, and 11.5% (3/26) in Group B with significant difference (P<0.05). Group C's 5 year survival rate was 11.1%(2/18). No significant difference was found betwee n Group B and C. Conclusion Application of pelvic lymphadenecto my on those with residual focus less than 2 cm can apparently improve the patien ts' survival rate. But when the diameter of the focus is larger than 2 cm, pelvi c lymphadenectomy is not necessary.